Postpartum Intrauterine Device: Use and Follow-Up of Users in the Maternity Ward of the Ratoma Communal Medical Center in Conakry, Guinea  

作　　者：Daniel W. A. Leno T. M. Millimouno I. Conté A. Diallo A. F. M. Soumah I. Sylla H. M. Keita D. Lamah A. Delamou T. Sy Daniel W. A. Leno;T. M. Millimouno;I. Conté;A. Diallo;A. F. M. Soumah;I. Sylla;H. M. Keita;D. Lamah;A. Delamou;T. Sy(Chair of Gynecology-Obstetrics, Gamal Abdel Nasser University of Conakry, Conakry, Guinea;Research Unit, National Center for Training and Research in Rural Health of Maferinyah, Forécariah, Guinea)

机构地区：[1]Chair of Gynecology-Obstetrics, Gamal Abdel Nasser University of Conakry, Conakry, Guinea [2]Research Unit, National Center for Training and Research in Rural Health of Maferinyah, Forécariah, Guinea

出　　处：《Open Journal of Obstetrics and Gynecology》2023年第10期1711-1721,共11页妇产科期刊（英文）

摘　　要：Objective: The aim of this study was to describe the use of the postpartum intrauterine device in the maternity ward of the Ratoma communal medical center in Conakry. Methods: This was a descriptive cross-sectional study carried out between July 1^st 2015 and June 30 2016, i.e. a duration of one year. Results: A total of 551 patients received advice on various contraceptive methods. Most of this advice was given in the post-partum period (40.2%) and during antenatal care (39.1%). Of the patients advised, 87 (15.8%) used the intrauterine device. The majority of users (93%) were married and uneducated (63.2%), and 39.1% were poor. The majority (56.3%) of intra-uterine devices were inserted in the immediate post-partum period. The majority of women had no adverse events either during the first six weeks (n = 57;65.5%) or at 3^rd months (n = 75;86.2%) or 6^th months (n = 76;87.4%) after IUD insertion. Most users remained complication-free throughout the follow-up period (n = 76;87.4% at 6^th weeks and 3^rd months, and n = 77;88.5% at 6^th months). The continuation rate was 89.7% at 6 weeks and 3^rd months, and 87.4% at 6^th months after insertion. The majority of users (87.0%) were satisfied with the care they received. Conclusion: This study showed very few complications among intrauterine device users, and high continuation and satisfaction rates. The intrauterine device is a long-acting, effective, reversible and safe contraceptive that can be used by most women for birth spacing in Guinea, where women do not regularly visit health facilities.Objective: The aim of this study was to describe the use of the postpartum intrauterine device in the maternity ward of the Ratoma communal medical center in Conakry. Methods: This was a descriptive cross-sectional study carried out between July 1^st 2015 and June 30 2016, i.e. a duration of one year. Results: A total of 551 patients received advice on various contraceptive methods. Most of this advice was given in the post-partum period (40.2%) and during antenatal care (39.1%). Of the patients advised, 87 (15.8%) used the intrauterine device. The majority of users (93%) were married and uneducated (63.2%), and 39.1% were poor. The majority (56.3%) of intra-uterine devices were inserted in the immediate post-partum period. The majority of women had no adverse events either during the first six weeks (n = 57;65.5%) or at 3^rd months (n = 75;86.2%) or 6^th months (n = 76;87.4%) after IUD insertion. Most users remained complication-free throughout the follow-up period (n = 76;87.4% at 6^th weeks and 3^rd months, and n = 77;88.5% at 6^th months). The continuation rate was 89.7% at 6 weeks and 3^rd months, and 87.4% at 6^th months after insertion. The majority of users (87.0%) were satisfied with the care they received. Conclusion: This study showed very few complications among intrauterine device users, and high continuation and satisfaction rates. The intrauterine device is a long-acting, effective, reversible and safe contraceptive that can be used by most women for birth spacing in Guinea, where women do not regularly visit health facilities.

关 键 词：Postpartum Intrauterine Device USE FOLLOW-UP Coronthie Communal Med-ical Center Conakry GUINEA 

分 类 号：R73[医药卫生—肿瘤]